Strategic Partners A/S (CPH:STRAP)
Denmark · Delayed Price · Currency is DKK 645.00
0.00 (0.00%)
Apr 20, 2026, 1:31 PM CET
Strategic Partners Employees
Strategic Partners had 1 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
309.00K DKK
Profits / Employee
-859.00K DKK
Market Cap
26.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1 | 0 | - |
| Dec 31, 2023 | 1 | 0 | - |
| Dec 31, 2022 | 1 | -61 | -98.39% |
| Dec 31, 2021 | 62 | -79 | -56.03% |
| Dec 31, 2020 | 141 | 55 | 63.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 69,505 |
| Demant | 26,704 |
| Coloplast | 16,983 |
| Genmab | 2,973 |
| Gubra | 300 |
| BioPorto | 46 |
| Scandinavian Medical Solutions | 29 |
| Monsenso | 10 |
Strategic Partners News
- 6 years ago - Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe - GlobeNewsWire
- 6 years ago - Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ordinary shares in Europe - GlobeNewsWire
- 6 years ago - Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering - GlobeNewsWire
- 6 years ago - Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe - GlobeNewsWire
- 6 years ago - Orphazyme A/S provides update on previously announced global offering - GlobeNewsWire
- 6 years ago - Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C - GlobeNewsWire
- 6 years ago - Denmark's Orphazyme files to go public on Nasdaq - Market Watch